Multiple Sclerosis, Secondary Progressive Clinical Trials in Palo Alto, California

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis